CL67

CL67 is a small molecule drug identified by Sarah Welsh and developed in Professor Stephen Neidle’s laboratory at University College London. It is being investigated as an anti-cancer strategy for kidney cancer. The drug functions by binding to and stabilizing G-quadruplex structures within the DNA of the Hypoxia-Inducible Factor (HIF)-1α and HIF-2α genes. This action prevents the production of HIF-1α and HIF-2α proteins, thereby inhibiting the HIF pathway, which is constitutively active in over 95% of kidney cancer cells and crucial for their survival and growth. Pre-clinical studies have shown CL67 to be effective in inhibiting kidney cancer cell growth in vitro and in animal models, with a favorable toxicity profile.